BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36540923)

  • 21. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
    Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
    Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
    [No Abstract]   [Full Text] [Related]  

  • 22. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer.
    Cheng X; Xu S; Zhu Y; Wu J; Bao J; Yu H; Zhang L
    Eur J Clin Invest; 2022 Apr; 52(4):e13721. PubMed ID: 34855206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.
    Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P
    World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The study of influence factors on (131)I treatment of differentiated thyroid carcinoma with lymph node metastases.
    Ye ZY; Wang H; Fu HL; Li JN; Zou RJ; Gu ZH; Wu JC
    Clin Imaging; 2009; 33(3):221-5. PubMed ID: 19411029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
    Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL
    Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macroscopic extranodal extension is an independent predictor of lung metastasis in papillary thyroid cancer.
    Hei H; Gong W; Zheng C; Zhou B; Qin J
    Endocrine; 2022 Jun; 77(1):73-79. PubMed ID: 35389141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
    Zhao S; Zhao Y; Zhao Y; Wang G
    Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
    Lin Y; Qin S; Yang H; Shi F; Yang A; Han X; Liu B; Li Z; Ji Q; Tang L; Deng Z; Ding Y; Fu W; Xie X; Li L; He X; Lv Z; Ma Q; Shen Z; Guo Z; Chen Z; Cui Y; Tan J; Gao Z; Jing S; Lu K; Luo X; Zhang Y; Fang Y; Li Z; Cheng Y; Lei S; Luan S; Chen G; Wang G; Wu L; Liu L
    Clin Cancer Res; 2023 Aug; 29(15):2791-2799. PubMed ID: 37184934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
    Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
    Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 34. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
    Watanabe K; Igarashi T; Uchiyama M; Ojiri H
    Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
    Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
    Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
    Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
    Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
    [No Abstract]   [Full Text] [Related]  

  • 37. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
    Wu X; Gu H; Gao Y; Li B; Fan R
    Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
    Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
    Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence.
    Chu KP; Baker S; Zenke J; Morad A; Ghosh S; Morrish DW; McEwan AJBS; Williams DC; Severin D; McMullen TPW
    Thyroid; 2018 Jul; 28(7):902-912. PubMed ID: 29742993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.